Whitney Ijem
Stock Analyst at Canaccord Genuity
(4.45)
# 304
Out of 5,090 analysts
111
Total ratings
53.12%
Success rate
21.13%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Whitney Ijem
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GUTS Fractyl Health | Maintains: Buy | $6 → $8 | $2.04 | +292.16% | 2 | Nov 21, 2025 | |
| PVLA Palvella Therapeutics | Maintains: Buy | $90 → $148 | $100.49 | +47.28% | 7 | Nov 13, 2025 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Buy | $105 → $114 | $104.60 | +8.99% | 9 | Nov 10, 2025 | |
| GBIO Generation Bio Co. | Maintains: Buy | $9 → $10 | $5.36 | +86.57% | 3 | Aug 18, 2025 | |
| PASG Passage Bio | Maintains: Buy | $260 → $67 | $9.21 | +627.47% | 7 | Aug 14, 2025 | |
| TSHA Taysha Gene Therapies | Maintains: Buy | $11 → $14 | $5.05 | +177.23% | 11 | Aug 13, 2025 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Buy | $136 → $128 | $36.38 | +251.84% | 9 | Aug 8, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Hold | $424 → $411 | $455.48 | -9.77% | 9 | Aug 6, 2025 | |
| WVE Wave Life Sciences | Initiates: Buy | $19 | $7.49 | +153.67% | 1 | Aug 4, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $390 → $415 | $458.12 | -9.41% | 9 | Aug 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $11 → $10 | $3.32 | +201.20% | 9 | Jul 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $74 → $54 | $9.61 | +461.91% | 6 | Jun 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $68 → $66 | $7.13 | +825.67% | 6 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 → $6 | $1.41 | +325.53% | 6 | Mar 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $148 → $150 | $22.26 | +573.85% | 3 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $93 → $84 | $53.40 | +57.30% | 8 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $121.22 | - | 2 | Jan 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $120 → $240 | $5.75 | +4,073.91% | 4 | Jul 23, 2019 |
Fractyl Health
Nov 21, 2025
Maintains: Buy
Price Target: $6 → $8
Current: $2.04
Upside: +292.16%
Palvella Therapeutics
Nov 13, 2025
Maintains: Buy
Price Target: $90 → $148
Current: $100.49
Upside: +47.28%
Rhythm Pharmaceuticals
Nov 10, 2025
Maintains: Buy
Price Target: $105 → $114
Current: $104.60
Upside: +8.99%
Generation Bio Co.
Aug 18, 2025
Maintains: Buy
Price Target: $9 → $10
Current: $5.36
Upside: +86.57%
Passage Bio
Aug 14, 2025
Maintains: Buy
Price Target: $260 → $67
Current: $9.21
Upside: +627.47%
Taysha Gene Therapies
Aug 13, 2025
Maintains: Buy
Price Target: $11 → $14
Current: $5.05
Upside: +177.23%
Ultragenyx Pharmaceutical
Aug 8, 2025
Maintains: Buy
Price Target: $136 → $128
Current: $36.38
Upside: +251.84%
Vertex Pharmaceuticals
Aug 6, 2025
Maintains: Hold
Price Target: $424 → $411
Current: $455.48
Upside: -9.77%
Wave Life Sciences
Aug 4, 2025
Initiates: Buy
Price Target: $19
Current: $7.49
Upside: +153.67%
Alnylam Pharmaceuticals
Aug 1, 2025
Maintains: Buy
Price Target: $390 → $415
Current: $458.12
Upside: -9.41%
Jul 25, 2025
Maintains: Buy
Price Target: $11 → $10
Current: $3.32
Upside: +201.20%
Jun 3, 2025
Maintains: Buy
Price Target: $74 → $54
Current: $9.61
Upside: +461.91%
May 13, 2025
Maintains: Buy
Price Target: $68 → $66
Current: $7.13
Upside: +825.67%
Mar 13, 2025
Maintains: Buy
Price Target: $18 → $6
Current: $1.41
Upside: +325.53%
Nov 7, 2024
Maintains: Buy
Price Target: $148 → $150
Current: $22.26
Upside: +573.85%
Oct 30, 2024
Maintains: Hold
Price Target: $93 → $84
Current: $53.40
Upside: +57.30%
Jan 21, 2020
Downgrades: Neutral
Price Target: n/a
Current: $121.22
Upside: -
Jul 23, 2019
Upgrades: Overweight
Price Target: $120 → $240
Current: $5.75
Upside: +4,073.91%